Integrin modulators: a patent review

Bibliography

• Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16
   PubMed Web of Science ®Google Scholar
• Humphries MJ. Integrin structure. Biochem Soc Trans 2000;28:311-39
   PubMed Web of Science ®Google Scholar
• Geiger B, Spatz JP, Bershadsky AD. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 2009;10:21-33
   PubMed Web of Science ®Google Scholar
• Mould AP, Humphries MJ. Cell biology - adhesion articulated. Nature 2004;432:27-8
   PubMed Web of Science ®Google Scholar
• Xiao T, Takagi J, Coller BS, et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004;432:59-67
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010;11:288-300
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-87
   PubMed Web of Science ®Google Scholar
• Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 2002;4:E65-8
   PubMed Web of Science ®Google Scholar
• Legate K, Wickström S, Fässler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009;10(23):397-418
   Google Scholar
• Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010;9:804-20
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7
   PubMed Web of Science ®Google Scholar
• Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-3
   PubMed Web of Science ®Google Scholar
• Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010;339:269-80
   PubMed Web of Science ®Google Scholar
• Vanderslice P, Woodside DG. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 2006;15:1235-55
   PubMed Web of Science ®Google Scholar
• Kuijpers TW, Van Lier RA, Hamann D, et al. Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J Clin Invest 1997;100:1725-33
   PubMed Web of Science ®Google Scholar
• Miller LJ, Schwarting R, Springer TA. Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J Immunol 1986;137:2891-900
   PubMed Web of Science ®Google Scholar
• de Fougerolles AR, Springer TA. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function associated molecule 1 on resting lymphocytes. J Exp Med 1992;175:185-90
   PubMed Web of Science ®Google Scholar
• Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-31
   PubMed Web of Science ®Google Scholar
• Dove A. CD18 trials disappoint again. Nat Biotechnol 2000;18:817-18
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1-233
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000542/human_med_001012.jsp [Last access 15 June 2013]
   Google Scholar
• Martin X, Da Silva M, Virieux SR, et al. Protective effect of an anti-LFA 1 monoclonal antibody (odulimomab) on renal damage due to ischemia and kidney autotransplantation. Transplant Proc 2000;32:481
   PubMed Web of Science ®Google Scholar
• Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012;33:405-12
   PubMed Web of Science ®Google Scholar
• Aids Research LLC. LFA-1 alpha subunit antibodies and methods of use. US6919077; 2005
   Google Scholar
• Anderson ME, Siahaan TJ. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003;24:487-501
   PubMed Web of Science ®Google Scholar
• Suchard SJ, Stetsko DK, Davis PM, et al. An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis. J Immunol 2010;184:3917-26
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00162253 [Last access 15 June 2013]
   Google Scholar
• Licentia LTD. Novel peptide ligands of leukocyte integrins. WO02072618; 2002
   Google Scholar
• Lee SW, Hwang BS, Kim MH. Inhibition of LFA-1/ICAM-1-mediated cell adhesion by stilbene derivatives from Rheum undulatum. Arch Pharm Res 2012;35:1763-70
   PubMed Web of Science ®Google Scholar
• Korea Institute of Bioscience and Biotechnology. Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from Piper Nigrum for the prevention and treatment of inflammatory disease. WO002009041787; 2009
   Google Scholar
• Hemler ME, Elices MJ, Parker C, Takada Y. Structure of the integrin VLA-4 and its cell–cell and cell–matrix adhesion functions. Immunol Rev 1990;114:45-65
   PubMed Web of Science ®Google Scholar
• Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185-95
   PubMed Web of Science ®Google Scholar
• Komoriya A, Green LJ, Mervic M, et al. The minimal essential sequence for a major cell type-specific adhesion site (CS-1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Biol Chem 1991;266:15075-9
   PubMed Web of Science ®Google Scholar
• Clements JM, Newham P, Shepherd M, et al. Identification of a key integrin-binding sequence in VCAM-1 homologous to the LDV active site in fibronectin. J Cell Sci 1994;107:2127-35
   PubMed Web of Science ®Google Scholar
• Shyjan AM, Bertagnolli M, Kenney CJ, Briskin MJ. Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. J Immunol 1996;156:2851-7
   PubMed Web of Science ®Google Scholar
• Bochner BS, Luscinskas FW, Gimbrone MA. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-7
   PubMed Web of Science ®Google Scholar
• Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin α4β7,on human leukocytes. J Immunol 1994;153:517-28
   PubMed Web of Science ®Google Scholar
• Kinashi T. Overview of integrin signaling in the immune system. Methods Mol Biol 2012;757:261-78
   PubMedGoogle Scholar
• Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-89
   PubMed Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005;4:510-18
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
   PubMed Web of Science ®Google Scholar
• MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;1:CD006097
   Google Scholar
• Available from: ClinicalTrials.gov NCT00083759 [Last accessed 15 June 2013]
   Google Scholar
• Burkly LC, Jakubowski A, Newman BM, et al. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol 1991;21:2871-5
   PubMed Web of Science ®Google Scholar
• Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci USA 2004;101:11058-63
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Seventer GAV, Horgan KJ, Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 1990;145:59-67
   PubMed Web of Science ®Google Scholar
• McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98
   PubMed Web of Science ®Google Scholar
• Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised I study of etrolizumab (rhuMAb b7) in moderate to severe ulcerative colitis. Gut 2013;62:1122-30
   PubMed Web of Science ®Google Scholar
• Elan Pharmaceuticals. Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies. US08246958; 2012
   Google Scholar
• Biogen Idec MA, Inc. Recombinant anti-VLA4 antibody molecules. US08226950; 2012
   Google Scholar
• Tilley JW. VLA-4 antagonists. Expert Opin Ther Patents 2002;12:991-1008
   Web of Science ®Google Scholar
• Ajinomoto Co., Inc. Novel phenylalanine derivative.WO2003070709; 2003
   Google Scholar
• Diamant Z, Kuperus J, Baan R, et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy 2005;35:1080-7
   PubMed Web of Science ®Google Scholar
• Crofts F, Pino M, DeLise B, et al. Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Defects Res B Dev Reprod Toxicol 2004;71:55-68
   PubMedGoogle Scholar
• Spence S, Vetter C, Hagmann W, et al. Effects of VLA-4 antagonists in a rat whole embryo culture. Teratology 2002;65:26-37
   PubMedGoogle Scholar
• Koga Y, Kainoh M. PP-065-15 Effect of an orally active small molecule alpha4beta1/alpha4beta7 integrin antagonist, TRK-170, on experimental colitis in mice. Int Immunol Meet Abstr 2010;22:iii138
   Google Scholar
• Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2012;11:131-9
   PubMed Web of Science ®Google Scholar
• White DJ, Puranen S, Johnson MS, Heino J. The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 2004;36:1405-10
   PubMed Web of Science ®Google Scholar
• Dickeson SK, Mathis NL, Rahman M, et al. Determinants of ligand binding specificity of the α1β1 and α2β1 integrins. J Biol Chem 1999;274:32182-91
   PubMed Web of Science ®Google Scholar
• Tulla M, Pentikäinen OT, Viitasalo T, et al. Selective binding of collagen subtypes by integrin α1L, α2L, and α10L domains. J Biol Chem 2001;276:48206-12
   PubMed Web of Science ®Google Scholar
• de Fougerolles AR, Sprague AG, Nickerson-Nutter CL, et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest 2000;105:721-9
   PubMed Web of Science ®Google Scholar
• Camper L, Holmvall K, Wängnerud C, et al. Distribution of the collagen-binding integrin alpha10beta1 during mouse development. Cell Tissue Res 2001;306:107-16
   Google Scholar
• Tiger CF, Fougerousse F, Grundström G, et al. alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells. Dev Biol 2001;237:116-29
   PubMed Web of Science ®Google Scholar
• Pozzi A, Moberg PE, Miles LA, et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor neovascularization. Proc Natl Acad Sci USA 2000;97:2202-7
   PubMed Web of Science ®Google Scholar
• Gardner HA. Integrin signaling in fibrosis and scleroderma. Curr Rheumatol Rep 1999;1:28-33
   PubMedGoogle Scholar
• Fiorucci S, Mencarelli A, Palazzetti B, et al. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity 2002;17:769-80
   PubMed Web of Science ®Google Scholar
• Ekholm E, Hankenson KD, Uusitalo H, et al. Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-deficient mice during bone fracture healing. Am J Pathol 2002;160:1779-85
   PubMed Web of Science ®Google Scholar
• Holtkötter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002;277:10789-94
   PubMed Web of Science ®Google Scholar
• Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999;353:351-4
   PubMed Web of Science ®Google Scholar
• Klein CE, Dressel D, Steinmayer T, et al. Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol 1991;115:1427-36
   PubMed Web of Science ®Google Scholar
• Hamaia SW, Pugh N, Raynal N, et al. Mapping of potent and specific binding motifs, GLOGEN and GVOGEA, for integrin α1β1 using collagen toolkits II and III. J Biol Chem 2012;287:26019-28
   PubMed Web of Science ®Google Scholar
• Karpusas M, Ferrant J, Weinreb PH, et al. Crystal structure of the alpha1beta1 integrin I domain in complex with an antibody Fab fragment. J Mol Biol 2003;327:1031-41
   PubMed Web of Science ®Google Scholar
• Available from: http://www.glenmarkpharma.com/GLN_DWL/uploads/Glenmark_MDA_Q1_FY%2012.pdf [Last access 15 June 2013]
   Google Scholar
• Carbonell WS, DeLay M, Jahangiri A, et al. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 2013;73:3145-54
   PubMed Web of Science ®Google Scholar
• Choi S, Vilaire G, Marcinkiewicz C, et al. Small molecule inhibitors of integrin a2b1. J Med Chem 2007;50:5457-62
   PubMed Web of Science ®Google Scholar
• Belkin AM, Stepp MA. Integrins as receptors for laminins. Microsc Res Tech 2000;51:280-301
   PubMed Web of Science ®Google Scholar
• Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dyn 2000;218:213-34
   PubMed Web of Science ®Google Scholar
• Mercurio AM, Rabinovitz I, Shaw LM. The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001;13:541-5
   PubMed Web of Science ®Google Scholar
• Gilcrease MZ. Integrin signaling in epithelial cells. Cancer Lett 2007;247:1-25
   PubMed Web of Science ®Google Scholar
• Lipscomb EA, Simpson KJ, Lyle SR, et al. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res 2005;65:10970-6
   PubMed Web of Science ®Google Scholar
• Biogen Idec MA, Inc. Anti-alpha 6 beta 4 integrin antibodies and uses thereof. WO002008127655; 2008
   Google Scholar
• Subbaram S, Dipersio CM. Integrin α3β1 as a breast cancer target. Expert Opin Ther Targets 2011;15:1197-210
   PubMed Web of Science ®Google Scholar
• Scott TR, Borick HP, Swire-Clark GA, et al. Inhibition of pathogenic agents including alpha6beta1 integrin receptor of alpha6beta4 integrin receptor at a surface. US20060275256; 2006
   Google Scholar
• Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991;65:359-62
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25
   PubMed Web of Science ®Google Scholar
• Hawiger J, Timmons S, Kloczewiak M, et al. Gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. Proc Natl Acad Sci USA 1982;79:2068-71
   PubMed Web of Science ®Google Scholar
• Doolittle RF, Watt KW, Cottrell BA, et al. The amino acid sequence of the alpha-chain of human fibrinogen. Nature 1979;280:464-8
   PubMed Web of Science ®Google Scholar
• Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and αvβ3 integrins. Circulation 1998;98:1085-91
   PubMed Web of Science ®Google Scholar
• Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066-73
   PubMed Web of Science ®Google Scholar
• Hartman GD, Egbertson MS, Halczenko W, et al. Non-peptide fibrinogen receptor antagonists. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4640-2
   PubMed Web of Science ®Google Scholar
• The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43
   PubMed Web of Science ®Google Scholar
• Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. J Am Med Assoc 1999;282:2058-67
   PubMed Web of Science ®Google Scholar
• Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des 2004;10:1587-96
   PubMed Web of Science ®Google Scholar
• Rockefeller University, National Institute for Health, Mount Sinai School of Medicine. Organic compounds. WO2012009688; 2012
   Google Scholar
• The Rockefeller University. Organic compounds. WO002008057601; 2008
   Google Scholar
• Piramal Imaging SA. Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of trombi. WO002013023795; 2013
   Google Scholar
• Duke University. Reversible platelet inhibition. US20120264815; 2012
   Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70
   PubMed Web of Science ®Google Scholar
• Plow EF, Haas TK, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275:21785-8
   PubMed Web of Science ®Google Scholar
• Robinson SD, Hodivala-Dilke KM. The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011;23:630-7
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
   PubMed Web of Science ®Google Scholar
• Koistinen P, Ahonen M, Kähäri VM, Heino J. alphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma. Int J Cancer 2004;112:61-70
   PubMed Web of Science ®Google Scholar
• Labelle H, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012;2:1091-99
   PubMed Web of Science ®Google Scholar
• Zhao H, Kitaura H, Sands MS, et al. Critical role of beta3 integrin in experimental postmenopausal osteoporosis. J Bone Miner Res 2005;20:2116-23
   PubMed Web of Science ®Google Scholar
• Masarachia P, Yamamoto M, Leu CT, et al. Histomorphometric evidence for echistatin inhibition of bone resportion in mice with secondary hyperparathyroidism. Endocrinology 1998;139:1401-10
   PubMed Web of Science ®Google Scholar
• Chellaiah MA, Hruska KA. The integrin alpha(v)beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 2003;72:197-205
   PubMed Web of Science ®Google Scholar
• Dechantsreiter MA, Planker E, Mathä B, et al. N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999;42:3033-40
   PubMed Web of Science ®Google Scholar
• Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010;10:753-68
   PubMed Web of Science ®Google Scholar
• Chatterjee J, Rechenmacher F, Kessler H. N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed 2013;52:254-69
   PubMed Web of Science ®Google Scholar
• Available from: http://www.merck.de/de/presse/extNewsDetail.html?newsId=C47977D13865FCB9C125 7B1D001EF9CA&newsType=1 [ [Last access 15 June 2013]
   Google Scholar
• Reardon DA, Neyns B, Weller M, et al. Cilengitide: an RGD-pentapeptide αvβ3 and αvβ5 inhibitor in development for gliobastoma and other malignancies. Future Oncol 2011;7:339-54
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01118676 [Last access 15 June 2013]
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01517776 [Last access 15 June 2013]
   Google Scholar
• Trikha M, Zhou Z, Nemeth JA, et al. CNTO95 a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiantiogenic activity in vivo. Int J Cancer 2004;110:326-35
   PubMed Web of Science ®Google Scholar
• Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011;1:154-88
   PubMed Web of Science ®Google Scholar
• Hersey P, Sosman J, O'Day S, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or – dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010;116:1526-34
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Davidson P, Rolland F, et al. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(v)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 2010;6:42-8
   PubMed Web of Science ®Google Scholar
• Mathis AE. Going to the source: integrin peptide therapy shows early promise in the treatment of vascular eye disease. Retin Physician 2012;9:70
   Google Scholar
• Breuss JM, Gillett N, Lu L, et al. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 1993;41:1521-7
   PubMed Web of Science ®Google Scholar
• Bates RC, Bellovin JI, Brown C, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005;115:339-47
   PubMed Web of Science ®Google Scholar
• Ahmed N, Pansino F, Baker M, et al. Association between alphavbeta6 integrin expression, elevated p42/44 KDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 2002;84:675-86
   PubMed Web of Science ®Google Scholar
• Thomas GJ, Nyström ML, Marshall JF. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006;35:1-10
   PubMed Web of Science ®Google Scholar
• Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105
   PubMed Web of Science ®Google Scholar
• Worthington JJ, Klementowicz JE, Travis MA. TGF beta: a sleeping giant awoken by integrins. Trends Biochem Sci 2011;36:47-54
   PubMed Web of Science ®Google Scholar
• Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans 2009;37:849-54
   PubMed Web of Science ®Google Scholar
• van Aarsen LA, Leone DR, Ho S, et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 2008;68:561-70
   PubMed Web of Science ®Google Scholar
• Eberlein C, Kendrew J, McDaid K, et al. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene 2012; doi: 10.1038/onc.2012.460
   PubMed Web of Science ®Google Scholar
• Goodman SL, Hölzemann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for avb6, avb5, and avb3 integrins. J Med Chem 2002;45:1045-51
   PubMed Web of Science ®Google Scholar
• Bochen A, Marelli UK, Otto E, et al. Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes 51 and v6: conformational control through flanking amino acids. J Med Chem 2013;56:1509-19
   PubMed Web of Science ®Google Scholar
• Aota S, Nomizu M, Yamada KM. The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 1994;269:24756-61
   PubMed Web of Science ®Google Scholar
• Tuckwell DS, Ayad S, Grant ME, et al. Conformation dependence of integrin-type II collagen binding. Inability of collagen peptides to support alpha 2 beta 1 binding, and mediation of adhesion to denatured collagen by a novel alpha 5 beta 1-fibronectin bridge. J Cell Sci 1994;107:993-1005
   PubMed Web of Science ®Google Scholar
• Bhaskar V, Zhang D, Fox M, et al. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007;5:61
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Sedgewick G, Ramakrishnan S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res 2007;67:10813-22
   PubMed Web of Science ®Google Scholar
• Bell-McGuinn KM, Matthews CM, Ho SN, et al. A phase II, single -arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 2011;121:273-9
   PubMed Web of Science ®Google Scholar
• Almokadem S, Belani CP. Volociximab in cancer. Expert Opin Biol Ther 2012;12:251-7
   PubMed Web of Science ®Google Scholar
• Zahn G, Vossmeyer D, Stragies R, et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol 2009;127:1329-35
   PubMedGoogle Scholar
• Stragies R, Osterkamp F, Zischinsky G, et al. Design and synthesis of a new class of selective integrin α5β1 antagonists. J Med Chem 2007;50:3786-94
   PubMedGoogle Scholar
• Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503
   PubMed Web of Science ®Google Scholar
• Heckmann D, Meyer A, Laufer B, et al. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. ChemBioChem 2008;9:1397-407
   PubMed Web of Science ®Google Scholar
• Rechenmacher F, Neubauer S, Polleux J, et al. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro. Angew Chem Int Ed 2013;52:1572-75
   PubMed Web of Science ®Google Scholar
• Rechenmacher F, Neubauer S, Mas-Moruno C, et al. A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion. Chem Eur J 2013;19:9218-223.
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167-70
   PubMed Web of Science ®Google Scholar
• van der Flier A, Badu-Nkansah K, Whittaker CA, et al. Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development. Development 2010;137:2439-49
   Google Scholar
• Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009;15:392-400
   PubMed Web of Science ®Google Scholar
• Weller M, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med 2009;15:726-6
   PubMed Web of Science ®Google Scholar
• Zaidel-Bar R, Itzkovitz S, Ma'ayan A, et al. Functional atlas of the integrin adhesome. Nat Cell Biol 2007;9:858-68
   PubMed Web of Science ®Google Scholar
• Funashi Y, Sugi NH, Semba T, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on endothelium. Cancer Res 2002;62:6116-23
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GP, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012;153:1050-60
   PubMed Web of Science ®Google Scholar
• SARcode. Modulators of cellular adhesion. US020120035154; 2012
   Google Scholar
• Norvatis AG. Pharmaceutically active tetrahydro-pyrrolo[1,2-B]isothiazole-1, 1-dioxides. WO002007039616; 2007
   Google Scholar
• Norvatis AG. Pharmaceutically active diazepanes. WO002006111371; 2006
   Google Scholar
• Dominion Pharmakine. Novel inhibitors of the LFA-1/ICAM-1 interaction, and uses thereof. WO002007054128; 2007
   Google Scholar
• Norvatis AG. Lymphocyte Function Antigen-1 antagonists. WO00199901258; 1999
   Google Scholar
• Daiichi Sankyo Co., Ltd. VLA-4 inhibitory drug. US000008129366; 2012
   Google Scholar
• Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4. US000007820687; 2010
   Google Scholar
• Daiichi Sankyo Co., Ltd. Cyclohexanecarboxylic acid compound. US000007893279; 2011
   Google Scholar
• Daiichi Pharmaceuticals Co Ltd. VLA-4 inhibitor compounds. US020070054909; 2007
   Google Scholar
• Elan Pharmaceuticals, Inc. Multimeric VLA-4 Antagonists comprising polymer moieties. US020120329807; 2012
   Google Scholar
• Elan Pharmaceuticals, Inc. Multimeric VLA-4 antagonists comprising polymer moieties. US000008263063; 2012
   Google Scholar
• Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4. US020100261715; 2010
   Google Scholar
• Wyeth, Elan Pharmaceuticals, Inc. 3-(Heteroaryl)alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4. US020080182850; 2008
   Google Scholar
• Elan Pharmaceuticals, Inc. Imidazolone phenylalanine derivatives. US000008030328; 2011
   Google Scholar
• Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. US000007973044; 2011
   Google Scholar
• Merck Patent GmbH. Method for the production of bicyclic aromatic amino acids and intermediate products thereof. US000007371854; 2008
   Google Scholar
• ICOS Corp. Aryl piperidine derivatives as VLA-1 integrin antagonists and uses thereof. WO2005019200; 2005
   Google Scholar
• Biogen Idec MA, Inc. Antibodies to VLA-1. US08084028; 2011
   Google Scholar
• The Trustees of Columbia University. Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof. US000005391481; 1995
   Google Scholar
• The Trustees of Columbia University in the City of New York. Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof. US000005788966; 1998
   Google Scholar
• Biogen, Inc. A blocking monoclonal antibody to VLA-1 and its use for the treatment of inflammatory disorders. WO002000072881; 2000
   Google Scholar
• Biotie Therapies Corp. Collagen receptor I-Domain binding modulators. WO002007031608; 2007
   Google Scholar
• Biotie Therapies Corp. Sulphonamide derivatives. WO002007034035; 2007
   Google Scholar
• Biotie Therapies Corp. Urea substituted sulphonamide derivatives. WO002010146236; 2010
   Google Scholar
• Nicholas Piramal India Ltd. Fibrinogen receptor antagonists and their use. WO002005035495; 2005
   Google Scholar
• MedImmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity. US2006040325; 2006
   Google Scholar
• Merck Patent GmbH. Engineered anti-alpha v- integrin hybrid antibodies. WO002009010290; 2009
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin. WO201083495; 2010
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Engineered integrin binding peptides. WO002008045252; 2008
   Google Scholar
• Universidad del Pais Vasco/Euskal Herriko Unibertsitatea. beta-Lactamic RGD cyclopeptides containing gamma (γ) turns. WO2006048473; 2006
   Google Scholar
• MolMed Spa. Conjugation product. WO002006067633; 2006
   Google Scholar
• Lykera Biomed SA. Cyclic RGD peptides of amino acids based on thiazoles or oxazoles as selective antagonists of the alfa alphavb3 integrin. WO2012062777; 2012
   Google Scholar
• University of Southern California. Integrin-binding small molecules. WO2007059195; 2007
   Google Scholar
• Universita' degli studi di Milano. Peptidomimetic compounds and preparation of biologically active derivatives. WO2006092722; 2006
   Google Scholar
• AstraZeneca AB. Antibodies directed to alphavbeta6 and uses thereof. WO2008112004; 2008
   Google Scholar
• Biogen Idec MA, Inc. Anti-alpha V beta 6 antibodies and uses thereof. WO002007008712; 2007
   Google Scholar
• Biogen, Inc. Anti-alphavbeta6 antibodies. WO2003100033; 2003
   Google Scholar
• Merck Patent GmbH. 3-Alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6. WO2003066594; 2003
   Google Scholar
• Merck Patent GmbH. Inhibitors of the integrin alpha v beta 6. WO0100660; 2001
   Google Scholar
• Merck Patent GmbH. Cyclic peptides derivatives as inhibitors of integrin alpha V beta 6. WO200105810; 2001
   Google Scholar
• Cancer Research Technology. alphavbeta6 peptide ligands and their uses. WO2007039728; 2007
   Google Scholar
• Merck Patent GmbH. Peptidic sulfonamides. WO002004069861; 2004
   Google Scholar
• AstraZeneca AB. Targeted binding agents directed to alpha5beta1 and uses therefor. WO002010072741; 2010
   Google Scholar
• Genentech, Inc. Anti-alpha5/beta1 antibody. US08350010; 2013
   Google Scholar
• Jerini AG. New compounds for the inhibition of angiogenesis and use of thereof. WO002005090329; 2005
   Google Scholar
• AstraZeneca. L-Alanine derivatives as alpha5 beta1 antagonists. WO002008093064; 2008
   Google Scholar
• AstraZeneca. N-[Heteroarylcarbonyl]-S-thienyl-L-alanine derivatives as alpha5beta1 antagonists. WO002008125811; 2008
   Google Scholar
• AstraZeneca. N-[Heteroarylcarbonyl]-3-thienyl-L-alanine derivatives as alpha5beta1 antagonists. US20080255183; 2008
   Google Scholar
• AstaZeneca. Chemical compounds. WO2007091046; 2007
   Google Scholar
• Jerini AG. New heterocyclic comounds for the inhibition of integrins and use thereof. WO002007131764; 2007
   Google Scholar
• Clanotech AG. Derivatives of quinoline-3-carboxylic acid and their medical use. WO2010133672; 2010
   Google Scholar
• AstraZeneca. L-Phenylalanine derivatives. US020090137601; 2009
   Google Scholar
• AstraZeneca. L-Alanine derivatives as alpha5betaL antagonists. WO002008093065; 2008
   Google Scholar
• Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26
   PubMed Web of Science ®Google Scholar
• Alon R, Feigelson SW. Chemokine-triggered leukocyte arrest: force-regulated bi-directional integrin activation in quantal adhesive contact. Curr Opin Cell Biol 2012;24:670-6
   PubMed Web of Science ®Google Scholar